UNCYUnicycive Therapeutics, Inc.Healthcare · Biotechnologyas of 2026-09-16
Horizon

Issued 2026-09-16 at $4.78 · now $4.78 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, UNCY has typically landed between $3.05 and $6.74 — a range of −36.2% to +41.0% from the issuance price $4.78.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

1,280 overlapping 1 month windows · 2021-07-122026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.756.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($4.78) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where UNCY has typically landed a month from the 2026-09-16 close of $4.78 — the range is history, not a prediction.

$3.05worst · -36.2%$6.74best · +41.0%
  • now $4.78 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $4.6 (-3.7%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $3.96$5.25
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $3.05$6.74
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 1,280 windows spanning 2021-07-12 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2024-07-15−52.7%−52.7%+0.0%
2021-07-13−51.8%−54.7%+0.0%
2024-05-28−51.6%−51.6%+8.4%
3 best
2023-02-07+384.6%−14.8%+384.6%
2023-03-02+346.0%−2.0%+436.0%
2023-03-03+344.9%+0.0%+446.9%

1,280 overlapping windows · 2021-07-122026-09-16 · not cherry-picked

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~6 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
60%
−7.8%
n=5
Feb
60%
+8.8%
n=5
Mar
40%
+59.7%
n=5
Apr
40%
−11.9%
n=5
May
40%
−6.0%
n=5
Jun
0%
−21.9%
n=5
Jul
20%
−6.9%
n=5
Aug
33%
−9.6%
n=6
Sep
50%
+1.9%
n=6
Oct
80%
+5.1%
n=5
Nov
60%
+6.1%
n=5
Dec
40%
+9.9%
n=5

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$9$4↑ buys↓ sales
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

21 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-05-14Kenkare-Mitra SaradirectorAward / grant42,100126,300Form 4
2026-05-14Kenkare-Mitra SaradirectorAward / grant84,20084,200Form 4
2026-05-14Laumas SandeepdirectorAward / grant84,20084,200Form 4
2026-05-14Laumas SandeepdirectorAward / grant42,100126,300Form 4
2026-05-14Gupta PramodofficerAward / grant169,500169,500Form 4
2026-05-14Jermasek DouglasofficerAward / grant169,500169,500Form 4
2026-05-14Gupta Shalabh K.directorAward / grant762,200762,200Form 4
2026-05-14Townsend JohnofficerAward / grant169,500169,500Form 4
2025-08-25Aggarwal GauravdirectorDisposition3,1990Form 4
2025-08-25Aggarwal GauravdirectorConversion652,9001,789,915Form 4
2025-08-25Aggarwal GauravdirectorConversion652,9001,789,915Form 4
2025-07-28Kenkare-Mitra SaradirectorAward / grant21,20039,200Form 4
2025-07-28Laumas SandeepdirectorAward / grant21,20041,286Form 4
2025-07-28Townsend JohnofficerAward / grant10,000101,557Form 4
2025-07-28Aggarwal GauravdirectorAward / grant21,20039,200Form 4
2025-07-28Jermasek DouglasofficerAward / grant10,000215,500Form 4
2025-07-28Gupta PramodofficerAward / grant90,000301,986Form 4
2025-07-28Gupta Shalabh K.directorAward / grant325,000968,951Form 4
2025-02-18Aggarwal GauravdirectorDisposition6863,119Form 4
2025-02-18Aggarwal GauravdirectorConversion1,400,00011,370,152Form 4
2025-02-18Aggarwal GauravdirectorConversion1,400,00011,370,152Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.